[MNK] Mallinckrodt plc


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 53.18 Change: 1.16 (2.23%)
Ext. hours: 53 Change: -0.18 (-0.34%)

chart MNK

Refresh chart

Strongest Trends Summary For MNK

MNK is in the medium-term down -36% in 2 months and down -50% below S&P in 1 year. In the long-term down -91% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment provides Acthar, an injectable biopharmaceutical drug for use in various indications, including neurology, rheumatology, nephrology, and pulmonology; Ofirmev and Xartemis XR for pain indications; EXALGO extended-release tablets to treat chronic pain; and GABLOFEN injections for use in the management of spasticity of cerebral or spinal origin. It also offers generics and active pharmaceutical ingredients (API), such as hydrocodone and hydrocodone-containing tablets, oxycodone and oxycodone-containing tablets, and methylphenidate HCl extended-release tablets, as well as biologics, medicinal opioids, synthetic controlled substances, acetaminophen products, and other active ingredients. The Global Medical Imaging segment provi

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 39.32% Sales Growth - Q/Q5.03% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.44% ROE-3.57% ROI-1.9%
Current Ratio2.86 Quick Ratio2.41 Long Term Debt/Equity2.75 Debt Ratio0.15
Gross Margin50.09% Operating Margin-4.3% Net Profit Margin-5.75% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities40.6 M Cash From Investing Activities-53 M Cash From Operating Activities365.5 M Gross Profit488.5 M
Net Profit98.8 M Operating Profit95.2 M Total Assets12.81 B Total Current Assets2.22 B
Total Current Liabilities775.7 M Total Debt3.99 B Total Liabilities7.63 B Total Revenue909.9 M
Technical Data
High 52 week36.08 Low 52 week12.33 Last close14.68 Last change-3.17%
RSI27.31 Average true range1.23 Beta1.37 Volume1.2 M
Simple moving average 20 days-10.94% Simple moving average 50 days-26.1% Simple moving average 200 days-39.23%
Performance Data
Performance Week-9.88% Performance Month-23.26% Performance Quart-32.69% Performance Half-52.75%
Performance Year-5.72% Performance Year-to-date-7.09% Volatility daily4.51% Volatility weekly10.1%
Volatility monthly20.69% Volatility yearly71.67% Relative Volume178.31% Average Volume2.21 M
New High New Low


2019-06-14 08:29:12 | Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

2019-06-13 06:45:00 | All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel Repository Corticotropin Injection Rheumatoid Arthritis RA Clinical Trial n=259 with Data Presented at the European Congress of Rheumatology 2019 EULAR

2019-06-11 06:55:00 | Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

2019-06-10 08:07:00 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.

2019-06-06 16:41:08 | Mallinckrodt Down After Agreement with DOJ for Litigation

2019-06-06 09:31:01 | Why Is Mallinckrodt MNK Down 47.4% Since Last Earnings Report?

2019-06-05 17:10:08 | Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies

2019-06-05 13:59:00 | Mallinckrodt's stock falls after it expects to pay more than $15 million to resolve DOJ investigation

2019-06-05 12:46:00 | Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation Activities

2019-05-31 17:37:00 | RM LAW Announces Investigation of Mallinckrodt plc

2019-05-31 11:29:00 | Mallinckrodt Stock is Falling Because the Wheels Might ‘Finally Come Off’

2019-05-31 06:55:00 | Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference

2019-05-30 07:48:11 | Cara Shares Up on Positive Phase III Data for Itchiness Drug

2019-05-29 10:40:02 | Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

2019-05-29 06:55:00 | Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel Repository Corticotropin Injection Clinical Trial in Rheumatoid Arthritis RA to be Presented at the European Congress of Rheumatology 2019 EULAR

2019-05-28 12:43:26 | Mallinckrodt's Amitiza to stay with branded business after spin-off

2019-05-28 09:31:00 | Mallinckrodt Rises After Announcing Plans to Spin Off Specialty Generics Unit

2019-05-28 07:10:09 | Mallinckrodt to spin-off generics business, keep constipation drug

2019-05-28 06:45:00 | Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders

2019-05-23 19:57:48 | Cramer Remix: Why Chipotle's downgrade is misguided

2019-05-23 19:57:48 | Cramer Remix: Why Chipotle's downgrade is misguided

2019-05-23 19:14:05 | Cramer: Mallinckrodt is too risky and not worth speculating on

2019-05-23 12:07:29 | This May Hurt a Little Or a Lot as Opioids Haunt Pharma Bonds

2019-05-22 15:42:07 | Mallinckrodt MNK Down After Filing Suit Against HHS and CMS

2019-05-22 14:43:00 | Wolf Popper LLP Announces Investigation on Behalf of Investors in Mallinckrodt plc

2019-05-22 11:26:56 | Mallinckrodt Slumps After Filing Acthar Lawsuit, But BMO Says It Can Take The Hit

2019-05-22 11:15:00 | Mallinckrodt Stock Could Take Another Plunge, Analyst Says

2019-05-22 06:00:00 | LOST MONEY IN MALLINCKRODT? Gibbs Law Group Investigates Potential Securities Claims on Behalf of Investors

2019-05-21 17:39:08 | Mallinckrodt International Finance SA -- Moody's downgrades Mallinckrodt's CFR to B2; outlook remains negative

2019-05-21 16:40:00 | Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today

2019-05-21 16:30:00 | Mallinckrodt Announces Election of Carlos V. Paya, M.D., Ph.D. to its Board of Directors

2019-05-21 16:19:29 | Mallinckrodt Shares Fall 25%: What You Need To Know

2019-05-21 15:18:00 | Mallinckrodt Is Circling the Drain - Do Not Go Down With It

2019-05-21 15:13:25 | Mallinckrodt Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

2019-05-21 14:00:00 | Mallinckrodt shares crater after drug maker files suit to protect Medicaid patient access to Acthar

2019-05-21 13:41:26 | Mallinckrodt Plunge to Record Low Is a Win for Short Sellers

2019-05-21 12:43:00 | Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

2019-05-21 12:20:00 | Why Mallinckrodt Stock Is Tanking Today

2019-05-21 07:42:00 | UPDATE: Mallinckrodt stock slides 10% premarket after it files suit over Medicaid patient access to Acthar gel

2019-05-21 06:59:00 | Mallinckrodt Files Suit against U.S. Department of Health and Human Services HHS and Centers for Medicare and Medicaid Services CMS to Protect Medicaid Patient Access to Acthar® Gel

2019-05-17 07:41:47 | Coatue Management’s Latest Moves

2019-05-15 11:07:03 | Mallinckrodt Ends Enrollment in Phase III for Terlipressin

2019-05-14 10:17:00 | Here's Why Generic-Drug Manufacturers Were Down Monday

2019-05-14 06:55:00 | Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial

2019-05-13 17:21:00 | Lifshitz & Miller LLP Announces Investigation of Glencore plc, Kingstone Companies, Inc., Mallinckrodt PLC, Metro Bank PLC, Momo Inc., Nabriva Therapeutics PLC, National General Holdings Corp, and Zillow Group, Inc.

2019-05-08 16:00:08 | Mallinckrodt MNK Beats on Q1 Earnings & Sales, Raises View

2019-05-08 01:24:25 | Mallinckrodt MNK Q1 2019 Earnings Call Transcript

2019-05-07 17:50:57 | Edited Transcript of MNK earnings conference call or presentation 7-May-19 12:30pm GMT

2019-05-07 08:22:25 | Mallinckrodt stock swings up 16%, then down, after drugmaker beats earnings estimates and raises 2019 profit outlook

2019-05-07 08:04:37 | See what the IHS Markit Score report has to say about Mallinckrodt Plc.